Rocket Pharmaceuticals

Rocket Pharmaceuticals is an American clinical-stage biotechnology company that focuses on developing gene therapy treatment options for undertreated diseases, genetic disease that leads to bone marrow failure and potentially cancer, and pediatric disease. Rocket Pharmaceuticals is headquartered in New York.
Rocket Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Rocket Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Rocket Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Rocket Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Rocket Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Rocket Pharmaceuticals assets
Rocket Pharmaceuticals cash flows

Rocket Pharmaceuticals dividend policy

The company doesn't provide dividend

Rocket Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
RCKT:USRocket PharmaceuticalsCommon share-US77313F1066$18.59
Rocket Pharmaceuticals news
24.02.2022
Rocket Pharmaceuticals' GAAP loss for 2021 was $169.069 million, up 21% from $139.7 million the previous year.
03.11.2021
Rocket Pharmaceuticals' GAAP loss for 9M 2021 was $124.822 million, up 58.4% from $78.784 million in the previous year.
10.08.2021
Rocket Pharmaceuticals' GAAP loss for 6M 2021 was $74.704 million, up 50.3% from $49.704 million in the previous year.
11.05.2021
Rocket Pharmaceuticals' GAAP loss for 3 months of 2021 was $40.179 million, up 62.9% from $24.664 million in the previous year.
General information
Company nameRocket Pharmaceuticals
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address430 East 29th Street Suite 1040 New York, NY 10016 United States
Mailing address430 East 29th Street Suite 1040 New York, NY 10016 United States
Websiteir.rocketpharma.com
Information disclosurewww.sec.gov